How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: The case of lymph node staging in melanoma

Journal of Clinical Pathology

Volumn 56, Issue 4, 2003, Pages 283-286

  Mijnhout, G S ^a   Hoekstra, O S ^a   Van Lingen, A ^a   Van Diest, P J ^a   Ader H J ^a   Lammertsma, A A ^a   Pijpers, R ^a   Meijer, S ^a   Teule, G J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISSECTION; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORPHOMETRICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037393634     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.4.283     Document Type: Article

References (32)

1. van Diest PJ, Torrenga H, Meijer S, et al. Pathologic analysis of sentinel lymph nodes. Semin Surg Oncol 2001;20:238-45.
2. Statius Muller MG, Van Leeuwen PA, Van Diest PJ, et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg 2002;26:1405-11.
3. Statius Muller MG, van Leeuwen PA, van Diest PJ, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001;11:303-7.
4. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001;91:2401-8.
5. Statius Muller MG, Borgstein PJ, Pijpers R, et al. Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann Surg Oncol 2000;7:461-8.
6. Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999;6:315-21.
7. Silverman DHS, Hoh CK, Seltzer MA, et al. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiation Oncol 1998;8:183-96.
8. Nieweg OE. Potential applications of positron emission tomography in surgical oncology. Eur J Surg Oncol 1994;20:415-24.
9. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
10. Warburg O. Uber den stoffzechsel der tumoren. Berlin: Springer, 1926.
11. Greco M, Crippa F, Agresti R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:630-5.
12. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
13. Rinne D, Baum RP, Hör G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography. Results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
14. Macfarlane DJ, Sondak V, Johnson T, et al. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-6.
15. Wagner JD, Schauwecker D, Hutchins G, et al. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181-9.
16. Torrenga H, Licht J, van der Hoeven JJ, et al. Re: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:1659-61.
17. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61.
18. Pijpers R, Borgstein PJ, Meijer S, et al. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intra-operative gamma probe and vital dye guidance. World J Surg 1997;21:788-93.
19. van Diest PJ, Peterse HL, Borgstein PJ, et al. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999;26(suppl):S43-9.
20. van Diest PJ. Histopathologic workup of sentbel lymph nodes: how much is enough? J Clin Pathol 1999;52:871-3.
21. Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological workup. J Clin Pathol 1999;52:922-4.
22. Mijnhout GS, Pijpers R, Hoekstra OS, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluoro-deoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1999;85:1199-201.
23. Giard RWM, Coebergh JWW. Increasingly sophisticated detection of lymph node metastases: the problems of stage migration. Ned Tijdschr Geneeskd 1999;143:1766-71.
24. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? J Nucl Med 2000;41:1491-4.
25. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-15.
26. Wagner JD, Schauwecker DS, Davidson D, et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-42.
27. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-8.
28. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter selective lymphadenectomy trial group. Ann Surg 1999;230:453-65.
29. Mastrangelo M. Conference report 3rd international conference adjuvant therapy of malignant melanoma. Melanoma Res 1999;9:306-8.
30. Eggermont AMM. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eur J Cancer 1998;34:S22-6.
31. Testori A, Lazzari I, Paganelli G, et al. Sentinel node biopsy: the best method to stage melanoma patients for adjuvant trials. Melanoma Res 1999;9:322.
32. Tallarida RJ. Pocketbook of integrals and mathematical formulas. New York: CRC Press, 1992.